Sep 15, 2023, 07:23 AM by

BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at a premium of NT$65 (~US$2.03), raising a total of NT$1.4625 billion (~US$45.8 million). The rights issue was fully paid on 31st August 2023, four days early compared to the scheduled date of 4th September.

Sep 15, 2023, 07:23 AM by

Torx® Software Limited has launched a major international collaboration with CDD Vault, which will create a shared digital ecosystem for drug discovery data

Sep 15, 2023, 07:23 AM by

SMi Systems has secured a patent from the UK Intellectual Property Office for the single-molecule imaging technologies that underpin its super-resolution multi-omic platform.

Sep 15, 2023, 07:23 AM by

Central California Alliance for Health (CCAH), just announced they selected ZeOmega’s care management solution to support its 420,000+ Medi-Cal members, including those in the most vulnerable communities. ZeOmega’s platform will enable CCAH to pinpoint the care needs of at-risk members and champion CalAIM’s efforts to provide equitable, person-centered care across California. This partnership also reflects the increased demand for flexible and scalable technology solutions to support government-sponsored healthcare programs across the nation.

Sep 15, 2023, 07:23 AM by

Form Bio, the provider of advanced computational life sciences technology announced today capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates. With great progress to date but headwinds around safety and manufacturability, Form’s new solutions help therapy developers find the safest and highest yielding versions of their therapies.

Sep 15, 2023, 07:23 AM by

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.

Sep 14, 2023, 01:00 AM by User Not Found

Bio-IT World | INNOVATIVE PRACTICES AWARDS—There are questions every research group could ask. At Regeneron’s Research and Preclinical department, tackling these questions meant accounting for more than 2,000 expensive and space-constrained instruments and seeking insight into how they are used.

Sep 13, 2023, 01:00 AM by User Not Found

Bio-IT World | Vaccine developers may want to consider designing formulations intended to prevent symptoms rather than infection, which the COVID-19 pandemic has demonstrated can be hard to do with any long-lasting effect.

Sep 12, 2023, 17:42 PM by

Takara Bio Europe has announced the launch of new high-quality grade mRNA production enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

Sep 12, 2023, 09:44 AM by

Lonza has released the MODA-ES® Module v4.0, an upgrade to its electronic batch record (EBR) module that enhances user experience and simplifies integration to expedite product release.

Sep 12, 2023, 01:00 AM by User Not Found

Bio-IT World | The recent discovery that the metastatic spread of breast cancer accelerates during sleep sparked a lively conversation at last month’s Next Generation Dx Summit about new paths of exploration for thwarting a deadly pan-cancer process claiming 12 lives worldwide every minute.

Sep 11, 2023, 08:49 AM by

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting The new AutoFox™ System promises to deliver hands-free, high-throughput Hydroxyl Radical Protein Footprinting for sophisticated Higher Order Structural (HOS) analysis

Sep 11, 2023, 08:49 AM by

GenNext & SCIEX Co-Market an advanced high order structure analysis workflow for biopharmaceutical research to spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics

Sep 8, 2023, 09:00 AM by

The Generative AI Strategic Collaborative reveals a slate of 10 clinical, ethics, technology, and regulatory experts for its national consortium

Sep 8, 2023, 09:00 AM by

BioIVT has implemented new tiered ‘fit-for-purpose’ study designs for metabolism, drug-drug interaction, and transporter programs, which utilize their electronic notebook system and automated reports, enabling them to better meet clients’ needs by reducing turnaround time, while maintaining the highest level of scientific expertise and quality.

Sep 8, 2023, 09:00 AM by

Sep 8, 2023, 01:00 AM by User Not Found

Bio-IT World | In the coming decades, many of the grand challenges that society faces, from global food shortages to disease control and climate change, has the opportunity to be solved by biology. To achieve this, we must enable researchers within the biotech and healthcare ecosystems to be more productive than ever by improving scale, reproducibility, and accessibility.

Sep 7, 2023, 08:19 AM by

Lactabico, an innovative biotech startup, has announced its graduation from the prestigious German Accelerator, a leading institution dedicated to propelling the growth of startups in the biotechnology sector.

Sep 7, 2023, 08:19 AM by

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation (UKRI), to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI), the two-year project will augment and validate the company’s ML technology, Alchemite™, as a tool to enhance productivity and yields of oligonucleotide therapeutic manufacture through performance prediction and optimisation of quality control strategies.

Sep 6, 2023, 14:45 PM by

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com